Preferential Rights Issue /
Företrädesemission 2020
Alzinova carries out a preferential rights issue of SEK 50 million to further finance the clinical development of ALZ-101. Below you will find information in regards to this issue and the prospectus.
- Read the full prospectus
- Read the “teaser”/short folder
- Application form / Anmälningssedel
- Press release 30 Sep. 2020, start of subscription period:
– Swedish
– English - Press release 29 Sep. 2020, publication of prospectus:
– Swedish
– English - Press release, 18 Sep. 2020:
– Swedish
– English - Link to our financial advisor – Redeye AB
- Interim report Q2, 2020
– Swedish
– English - Annual report 2019:
– Swedish
– English - Annual report 2018, Swedish
- Articles of Association, in Swedish
- Registration certificate Alzinova AB, in Swedish
- Terms and conditions warrants